Ascelia Pharma AB (publ) (ACE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you and welcome everyone to the webcast for Acelia Pharma's Q1 report for 2025. On this call, we will be making forward-looking statements. On today's call, we'll start with the recent key events and then head into our portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions. As mentioned, I am Magnus Krofertson, CEO of Acelia Pharma, and with me today I have Julie Veras Broeckren, Deputy CEO, and Andreas Norlin, Chief Scientific Officer. At Acelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglands is in registration phase as we have successfully completed the pivotal phase three clinical study SPARQL and we are preparing the MDA submission. Orviglands has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million globally. Oncrawl is ready to start phase two in the treatment of gastric cancer based on encouraging results in phase one and a high level of unmet medical need. We're based in Malmö, Sweden, and are listed on NASDAQ Stockholm. The first quarter of 2025 was eventful as we continued our preparation for the submission of the OverGlands NDA. I'd like to briefly mention some of the key highlights. The interest in the scientific and medical community continues to be strong, and in Q1, we announced the acceptance of three abstracts here of two oral presentations at ESCAR, which is the European Society of Gastrointestinal Radiology, which took place this week in Amsterdam. After the end of the quarter, we announced acceptance of a poster presentation at the ISPO conference in Canada, which is also this week about the burden of diseas...